



CODEN [USA]: IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.1840463>Available online at: <http://www.iajps.com>

Research Article

**EFFECTS OF CIGARETTES SMOKING ON PLATELET
BEHAVIOUR AND CLOT FEATURES IN HABITUAL
SMOKERS**

Mishari Saleh Alharbi¹, Mohammed Abdullah Alghamdi¹, Abdullah Musaad S Alkhathami¹, Ibrahim Abdulhamid Alghamdi¹, Jehad Tawfiq M Alhussaini¹, Hussam Abdullah M Alghamdi¹, Mazen Ayed Alghamdi¹, Lama Ayedh Aldkheelallah¹

¹ Medical intern, faculty of Medicine, Al-Baha University, Saudi Arabia.

Abstract:

Cigarette smoking (CS) continues to be a major health hazard, and it contributes significantly to cardiovascular morbidity and mortality. Cigarette smoking impacts all phases of atherosclerosis from endothelial dysfunction to acute clinical events, the latter being largely thrombotic. Both active and passive (environmental) cigarette smoke exposure predispose to cardiovascular events. To our knowledge, there have been no reports on the relationship between current cigarette smoking and clot features in subjects without any known cardiovascular risk factors. We sought to investigate whether plasma fibrin clot structure/function differ between healthy smokers and never-smokers.

Key Words: *Cigarette smoking (CS) - Platelets - plasma clot - Fibrinolysis - Red cell deformability - Blood viscosity - Plasma viscosity.*

Corresponding author:**Mishari Saleh Alharbi,**

Medical intern, faculty of Medicine,
Al-Baha University,
Saudi Arabia.

QR code



Please cite this article in press Mishari Saleh Alharbi et al., Effects of Cigarettes Smoking On Platelet Behaviour and Clot Features in Habitual Smokers., Indo Am. J. P. Sci, 2018; 05(12).

INTRODUCTION:

Tobacco use has predominantly negative effects on human health and concern about health effects of tobacco has a long history. Many researchers have been focusing primarily on cigarette tobacco smoking [1, 2]. Tobacco smoke contains more than fifty chemicals that cause cancer [3]. Tobacco also contains nicotine, which is a highly addictive psychoactive drug. When tobacco is smoked, nicotine causes physical and psychological dependency. Cigarettes sold in underdeveloped countries tend to have higher tar content, and are less likely to be filtered, potentially increasing vulnerability to tobacco smoking related disease in these regions [4]. Cigarette smoking is associated with an increased incidence of acute MI. Cessation of smoking significantly reduces this risk over a one- to three-year period with an exponential decline approaching the risk in ex-smokers within five years of cessation. Recent data indicate an immediate reduction in thrombotic events with smoking cessation. A preliminary, oral presentation study (presented by Sargent, Shepard, and Glantz at the 52nd Annual American College of Cardiology Conference in March 2003) reported that a citywide smoking ban in public places over a six-month period in Helena, Montana, reduced the incidence of acute MI by 60% during that time period. Furthermore, pathologic studies of sudden coronary death indicate that CS increased the risk of plaque rupture and acute thrombosis of a lipid-rich, thin-capped atheroma in men; in female smokers, the prevailing mechanism was plaque erosion with superimposed thrombosis. Acute cigarette smoke exposure may also increase coronary artery vascular resistance reducing coronary blood flow. Smoking may also be a risk factor for coronary vasospasm [5].

The prothrombotic effects of exposure to cigarette smoke have been repeatedly demonstrated to cause alterations in platelet function, antithrombotic/prothrombotic factors, and fibrinolytic factors. The following sections address the present knowledge regarding these effects. Platelets isolated from smokers exhibited an increased stimulated as well as spontaneous aggregation. After exposure to smokers' serum, platelets isolated from non-smokers demonstrated hyper aggregability. Cigarette smoking may decrease availability of platelet-derived NO and decrease platelet sensitivity to exogenous NO, leading to increased activation and adhesion [7]. Current smokers have higher fibrinogen levels that correlate with the number of cigarettes smoked. Ex-smokers have fibrinogen levels similar to non-smokers. Alterations of tissue factor (TF) and TF pathway inhibitor-1 (TFPI-1) and a consequent increase in thrombotic potential have also been

documented. Human umbilical vein endothelial cells exposed to serum from chronic smokers showed a significantly decreased TFPI-1 level and relatively higher but non-significant increase in TF level in culture. An increased TF immunoreactivity and an increase in TF activity were observed in atherosclerotic plaques isolated from apoE^{-/-} mice exposed to half of a non-filtered research cigarette five days a week, for eight weeks. In smokers 2 h after smoking two cigarettes, an increase in circulating TF activity has also been reported in human plasma [8]. Furthermore, higher red blood cell counts, hematocrits, blood viscosity, and an ongoing inflammatory process potentiate the prothrombotic process associated with smoke exposure [7,9,10].

RESULTS:

The biological mechanism linking smoking and clot features is complex and not fully understood. Besides clot features, proposed potential mechanisms by which smoking increases the risk of cardiovascular pathology include several other pathways: vascular endothelial dysfunction, systemic hemostatic and coagulation disturbances, and lipid abnormalities [11]. Many of these indexes including fibrinogen (marker of coagulation), fibrin d-dimer (a marker of cross-linked fibrin turnover), and tissue plasminogen activator antigen (t-PA, marker of endothelial dysfunction) have been identified as independent predictors of subsequent cardiovascular events in prospective studies conducted in healthy subjects. In addition, platelet hyper aggregation and activation, plasma viscosity, and plasminogen activator inhibitor (PAI) type I (marker of impaired fibrinolysis) levels have also been associated with cardiovascular morbidity and mortality in prospective studies. The effect of smoking on these variables has also been investigated in several cross-sectional studies, as will be discussed below. It has been demonstrated that the serum concentration of nitrate and nitrite, metabolic end-products of NO, is significantly decreased in smokers relative to that in nonsmokers.⁷⁴In cigarette smokers, low-density lipoprotein (LDL) is more prone to oxidation due to higher level of ROS and reactive nitrogen species [12,17]. Oxidatively modified LDL limits the bioactivity of endothelium-derived NO; and, in turn, the loss of NO bioactivity is associated with increased inflammatory cell entry into the arterial wall.⁷⁶Oxidatively modified LDL is taken up by macrophage scavenger receptors, promoting cholesterol ester accumulation and foam cell formation. Most recently, upregulation of the CD40/CD40L dyad and increased platelet/monocyte aggregation have been proposed as potential

contributors to the atherothrombotic consequences of smoking [18]. CD40-CD40 ligand couples, members of TNF family, are co-expressed by all of the major cellular players in atherosclerosis. In particular, smokers appeared to have elevated plasma levels of soluble CD40 and increased surface expression of CD40 on monocytes together with increased CD40 ligand on platelets. Furthermore, plasma cotinine concentrations correlated with CD40 and CD40 ligand expression, and with rate of platelet-monocyte aggregations. A recent study suggests that oxidatively modified LDL may play the role of initial trigger for CD40/CD40L expression in human endothelial and smooth-muscle cells. Dysfunctional endothelial cells lose their critical physiologic property of non adherence to circulating immune effector cells (monocytes, macrophages, T-lymphocytes, platelets). Some adhesion molecules are known to be elevated in plasma of smokers. Several groups reported significantly higher levels of soluble intracellular adhesion molecule (ICAM)-1 and P-selectin and E-selectin in current smokers than in nonsmokers among healthy women. A dose-dependent relationship was observed between plasma ICAM-1 concentration and daily cigarette consumption, plasma cotinine level, and exhaled carbon monoxide level. Generally, impaired endothelial function caused by cigarette smoking may lead to increased susceptibility of vasculature to atheroma formation and can be considered as a nearly feature of atherogenesis in humans. Furthermore, elevated levels of markers of fibrinolysis have been reported in healthy smokers [19-22]. t-PA, the main fibrinolytic activator, converting plasminogen to plasmin is synthesized by endothelial cells. In vivo studies have demonstrated major impairment of t-PA release from the vascular endothelium of smokers. The primary inhibitor of fibrinolysis is PAI-I, which inhibits plasminogen activation by binding with t-PA to form the PAI/t-PA complexes. Current smoking is associated with a significant increase in t-PA antigen, which represents mainly the circulating PAI/t-PA complexes and indicates impaired fibrinolytic activity in smokers. Supporting previous findings, plasma PAI-1 antigen and/or activity is significantly higher in smokers than in nonsmokers and is correlated with pack-year smoked. Plasmin promotes the degradation of fibrin within the thrombus, disintegrating clots, and hence maintains vascular patency. Fibrin d-dimer is a degradation product of cross-linked fibrin that is related to cardiovascular diseases risk. As been reported, smoking is positively associated with fibrin d-dimer [23-25]. The increased d-dimer in smokers probably reflects increased coagulation activation because this antigen is present in several

degradation products from the cleavage of cross-linked fibrin by plasmin. Taking into account possible adverse effects of abnormal fibrinolysis and excess coagulation on vascular health, further studies are essential to evaluate the impairment of the fibrinolytic system in smokers [26-28].

DISCUSSION:

Factors and mechanisms responsible for smoking-mediated vascular dysfunction

Human umbilical vein endothelial cells exposed to chronic smoker's serum have significant decreases in both basal and substance-P-stimulated t-PA release in culture with a significant alteration in t-PA/PAI-1 molar ratio. Similarly, decreased plasma t-PA antigen and activity were observed in smokers in samples isolated from brachial and coronary arteries after pharmacologic stimulation.

Therefore, CS is associated with dysfunctional thrombo-hemostatic mechanism(s) that promote the initiation and/or propagation of thrombus formation and limit its effective dissolution [29].

Cigarette smoke contains over 4,000 known components, of which only a few components have been examined in isolation. Carbon monoxide (CO) is one such component, but its effects on atherothrombotic disease have been equivocal. An earlier study suggested that CO could be responsible for smoking-related cardiovascular alterations. However, more recent data suggest that CO from cigarette smoke was an unlikely cause for atherosclerosis or thrombus. Polycyclic aromatic hydrocarbons found in the tar fraction of cigarette smoke have also been studied, and these components, at least in experimental models, accelerate atherosclerosis [30].

Nicotine in cigarette smoke is probably the most studied component. Although nicotine plays a major role in smoking-related increases in cardiac output, heart rate, and blood pressure, its role in CS-related atherothrombotic disease remains controversial [31]. Nicotine exposure alone had been reported to cause no change, a decrease, or an increase in EDV or NO availability. In various models, although high doses of nicotine favor atherogenic changes, the majority of current evidence suggests that nicotine, at concentrations similar to a smoker's blood level, has a minor effect on the initiation or propagation of atherosclerosis. Similarly, the effect of nicotine on thrombo-hemostatic factors such as platelets, fibrinogen, or t-PA, PAI-1 appears to be insignificant

in the setting of smoking. As mentioned earlier, nicotine is the known addictive substance in cigarette smoke, and its addictive qualities likely perpetuate exposure to the other more detrimental components [32].

Currently, free radical-mediated oxidative stress is emerging as the pivotal step for the development of atherosclerosis. In a setting of CS, free radicals could arise from: 1) the gas or tar phase of cigarette smoke; circulating or in situ-activated macrophages and neutrophils; and endogenous sources of reactive oxygen species such as uncoupled eNOS, xanthine oxidase, and the mitochondrial electron transport chain. A reaction between free radicals such as superoxide and NO not only decreases NO availability but also generates peroxynitrite, which further enhances the cellular oxidative stress [33]. Increased oxidative stress with the loss of the protective effect of NO tips the cellular balance towards a proatherogenic and prothrombotic milieu. Many of the abnormalities described above, including endothelial dysfunction, proinflammatory effects on the vessel wall, prothrombotic effects such as increased platelet reactivity, reduced endogenous fibrinolysis, and lipid peroxidation, can largely be explained by the effects of increased oxidative stress. Furthermore, antioxidants or agents that reduced the oxidative stress or increased NO availability have been shown to either improve or reverse the proatherogenic, proinflammatory, and prothrombotic attributes associated with CS.

Nonlinear dose effect of smoking on cardiovascular function

Although the association between CS and cardiovascular risk has clearly been demonstrated, an unanswered question is whether or not there is a linear dose effect. Several recent large epidemiologic studies showing a trend for more cardiovascular events in heavier active smokers have failed to find a significant dose-dependent correlation between cardiovascular risk and the number of cigarettes smoked or the pack-years of exposure. More recently, heavy and light active smokers had a similar decrease in brachial artery EDV and similar abnormalities of NO biosynthesis. Similarly, even with passive smoking, certain athero-thrombotic markers such as a reduced EDV and increased platelet activation were similar to that of active smoking. The data presented above suggest that the underlying biochemical and cellular processes may become saturated with small doses of toxic components from cigarette smoke causing a nonlinear dose-response on cardiovascular function. The exact mechanisms require further

studies [34,35].

CONCLUSIONS:

Epidemiologic studies have established worldwide that cigarette smoke exposure is an important cause of clot features leading to morbidity and mortality. Clinical and experimental studies indicate that either active or passive exposure promotes clot features, atherogenesis, and thrombosis in multiple vascular beds. Although the precise mechanisms responsible remain undetermined, free radical-mediated oxidative stress appears to play a central role in CS-mediated athero-thrombotic diseases. These free radicals could potentially arise directly from cigarette smoke and indirectly from endogenous sources as well. Furthermore, potentiated by multiple prothrombotic and antifibrinolytic effects, intravascular thrombosis is the predominant cause of acute cardiovascular events. An increasing body of epidemiologic, clinical, and experimental data also suggest that the pathophysiologic effects of cigarette smoke exposure on cardiovascular function may be nonlinear. Future studies investigating the potential cigarette smoke-inducible endogenous cellular mechanisms could further our understanding of the complex pathobiology of cigarette smoke and cardiovascular dysfunction.

REFERENCES:

1. Edwards R. The problem of tobacco smoking. *BMJ* 2004;328:217–2192 Tobacco control: country profiles.
2. Atlanta, GA: American Cancer Society, 20003 World health report 2002: Reducing risks, promoting healthy life.
3. Geneva, Switzerland: World Health Organization, 20024.
4. Crofton J, Bjartveit K. Smoking as a risk factor for chronic airways disease. *Chest* 1989; 96(3 suppl):307S–312S5.
5. Boyle P. Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of Euro-pean Cancer Experts Consensus Meeting, Helsinki, October 1996. *Lung Cancer* 1997; 17:1–606.
6. van der Vaart H, Postma DS, Timens W, et al. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. *Thorax* 2004; 59:713–7217.
7. Pryor W, Stone K. Oxidants in cigarette smoke radicals, hydrogen peroxides, peroxynitrate, and peroxynitrite. *Ann N Y Acad Sci* 1993; 28:12–278.
8. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic

pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. *Eur Heart J* 2005; 26:1765–177334.

34. Yarnell JW, Sweetnam PM, Runley A, et al. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caer-philly Study. *Arterioscler Thromb Vasc Biol* 2000; 20:271–27935.
35. Smith MR, Kinmonth KL, Luben RN, et al. Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. *Atherosclerosis* 2003; 169:331–337.